<?xml version="1.0" encoding="UTF-8"?>
<p id="Par91">However, in the 
 <italic>first stage</italic> of the disease, more symptomatic or at risk patients would require hospitalization, initial imaging, and laboratory tests. Therapeutic strategies in such cases focus in reducing viral replication and to passively enhance immunity. When disease progresses into a 
 <italic>second stage</italic> characterized by a viral pneumonia, the initial treatment might include a combination of antimalaria and macrolide antibiotics as well as antiinflammatory medications. Finally, the severely ill patient may present with systemic hyperinflammation, disseminated intravascular coagulation, and acute respiratory distress syndrome, requiring mechanical ventilation and supportive measures in a critical care unit. In this 
 <italic>third stage</italic> of the disease, the evaluation of several specific biomarkers would allow the administration of personalized endotype-driven treatment.
</p>
